Verastem CFO Daniel Calkins sells $423 in company stock

On September 21, 2026, Daniel Calkins, the Chief Financial Officer of Verastem Inc. (NASDAQ: VSTM), sold 55 shares of the company's common stock. The sale took place to comply with statutory withholding requirements related to the vesting of restricted stock units. Each share was sold for $7.7, resulting in a total sale value of $423. Since the transaction, the stock price has risen to $8.18, marking a 66% gain over the past six months.

Following the sale, Mr. Calkins continues to hold 118,014 shares of Verastem common stock. This includes 831 shares acquired through the company's 2018 Employee Stock Purchase Plan. According to InvestingPro analysis, the stock appears to be undervalued at its current levels, with 11 additional ProTips available to subscribers.

In recent news, Verastem reported its Q2 2026 earnings, surpassing Wall Street expectations. The company generated $40.07 million in revenue, significantly surpassing the forecasted $23.09 million. Net product sales amounted to $25.1 million, with an additional $15 million coming from a license payment. Despite the impressive results, Verastem reported an adjusted loss of $0.31 per share, which was better than the estimated $0.43 loss.

H.C. Wainwright reaffirmed its Buy rating for Verastem, setting a price target of $18.00, based on new data from a cancer trial presented at the International Gynecologic Cancer Society meeting. Mizuho, on the other hand, lowered its price target for Verastem shares to $13.00 from $14.00, while maintaining an Outperform rating, after the company's strong second-quarter performance.

The cancer trial data compared patients treated with avutometinib plus defactinib to those receiving conventional therapy.